Merck's Pneumococcal Vaccine Lands FDA Nod, Just Few Weeks After Its Rival

Merck's Pneumococcal Vaccine Lands FDA Nod, Just Few Weeks After Its Rival

Source: 
Benzinga
snippet: 

  • For the second time in five weeks, the FDA has approved a new pneumococcal conjugate vaccine, this time giving the nod to a shot from Merck & Co Inc MRK 1%.
  • The vaccine, Vaxneuvance, is designed to protect against 15 strains of pneumococcal bacteria. That’s two more strains than Prevnar 13, a product from rival Pfizer Inc PFE 1.05%.